<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Genprex Inc — News on 6ix</title>
<link>https://6ix.com/company/genprex-inc</link>
<description>Latest news and press releases for Genprex Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/genprex-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835790378dffbe2df0f84d9.webp</url>
<title>Genprex Inc</title>
<link>https://6ix.com/company/genprex-inc</link>
</image>
<item>
<title>Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting</title>
<link>https://6ix.com/company/genprex-inc/news/genprex-collaborators-to-present-positive-preclinical-data-on-diabetes-gene-therapy-for-type-2-diabetes-at-the-2026-american-society-of-gene-and-cell-therapy-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/genprex-inc/news/genprex-collaborators-to-present-positive-preclinical-data-on-diabetes-gene-therapy-for-type-2-diabetes-at-the-2026-american-society-of-gene-and-cell-therapy-annual-meeting</guid>
<pubDate>Tue, 28 Apr 2026 11:00:00 GMT</pubDate>
<description>Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present positive preclinical data on the Company's diabetes gene therapy drug candidate at the upcoming 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place May 11-15, 2026 in Boston, Mass. The collaborators will present preclinical d</description>
</item>
<item>
<title>Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting</title>
<link>https://6ix.com/company/genprex-inc/news/positive-clinical-data-on-biomarkers-in-patients-receiving-reqorsar-gene-therapy-to-be-released-at-the-2026-asco-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/genprex-inc/news/positive-clinical-data-on-biomarkers-in-patients-receiving-reqorsar-gene-therapy-to-be-released-at-the-2026-asco-annual-meeting</guid>
<pubDate>Wed, 22 Apr 2026 11:00:00 GMT</pubDate>
<description>Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract has been selected for publication at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 29 – June 2, 2026 in Chicago, Illinois. The abstract details positive clinical data from studies of predictive biomarkers in pat</description>
</item>
<item>
<title>Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy</title>
<link>https://6ix.com/company/genprex-inc/news/genprex-signs-sponsored-research-agreement-to-study-biomarkers-that-may-predict-patient-response-to-reqorsar-gene-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/genprex-inc/news/genprex-signs-sponsored-research-agreement-to-study-biomarkers-that-may-predict-patient-response-to-reqorsar-gene-therapy</guid>
<pubDate>Tue, 21 Apr 2026 11:00:00 GMT</pubDate>
<description>Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company has entered into a new Sponsored Research Agreement (SRA) with The University of Texas MD Anderson Cancer Center (UT MD Anderson) to study biomarkers that may predict patient response to Reqorsa® Gene Therapy (quaratusugene ozeplasmid), the Company's lead drug candidate that is in developm</description>
</item>
<item>
<title>Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting</title>
<link>https://6ix.com/company/genprex-inc/news/genprex-collaborators-present-positive-preclinical-data-on-the-use-of-reqorsar-gene-therapy-for-the-treatment-of-lung-cancer-at-the-2026-aacr-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/genprex-inc/news/genprex-collaborators-present-positive-preclinical-data-on-the-use-of-reqorsar-gene-therapy-for-the-treatment-of-lung-cancer-at-the-2026-aacr-annual-meeting</guid>
<pubDate>Mon, 20 Apr 2026 11:00:00 GMT</pubDate>
<description>Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting being held April 17-22, 2026 in San Diego, California. The collaborators presented positive preclinical data from studies of its lead drug candidate, Reqorsa® Gene Therapy (quaratusugen</description>
</item>
<item>
<title>Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting</title>
<link>https://6ix.com/company/genprex-inc/news/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsar-gene-therapy-for-the-treatment-of-lung-cancer-at-the-2026-aacr-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/genprex-inc/news/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsar-gene-therapy-for-the-treatment-of-lung-cancer-at-the-2026-aacr-annual-meeting</guid>
<pubDate>Wed, 18 Mar 2026 11:00:00 GMT</pubDate>
<description>Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present at the upcoming 2026 American Association for Cancer Research (AACR) Annual Meeting being held April 17-22, 2026 in San Diego, California. The collaborators will present positive preclinical data from studies of its lead drug candidate, Reqorsa® Gene Therap</description>
</item>
<item>
<title>Genprex to Participate at BIO Europe Spring 2026</title>
<link>https://6ix.com/company/genprex-inc/news/genprex-to-participate-at-bio-europe-spring-2026</link>
<guid isPermaLink="true">https://6ix.com/company/genprex-inc/news/genprex-to-participate-at-bio-europe-spring-2026</guid>
<pubDate>Tue, 10 Mar 2026 11:00:00 GMT</pubDate>
<description>Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that members from its executive leadership team will be attending and participating at BIO Europe Spring taking place March 23-25, 2026 in Lisbon, Portugal.</description>
</item>
<item>
<title>Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer</title>
<link>https://6ix.com/company/genprex-inc/news/genprex-strengthens-intellectual-property-portfolio-with-japanese-and-eu-patents-for-reqorsar-gene-therapy-in-combination-with-immunotherapies-to-treat-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/genprex-inc/news/genprex-strengthens-intellectual-property-portfolio-with-japanese-and-eu-patents-for-reqorsar-gene-therapy-in-combination-with-immunotherapies-to-treat-cancer</guid>
<pubDate>Mon, 23 Feb 2026 13:00:00 GMT</pubDate>
<description>Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Japanese Patent Office has issued a favorable Appeal Decision to grant a patent claiming the use of Reqorsa® Gene Therapy in combination with PD-L1 antibodies to treat cancer. Also, the European Patent Office has issued a Decision to Grant relating to a patent for the combination of REQORSA a</description>
</item>
<item>
<title>Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers</title>
<link>https://6ix.com/company/genprex-inc/news/genprex-announces-ip-australias-intent-130000148</link>
<guid isPermaLink="true">https://6ix.com/company/genprex-inc/news/genprex-announces-ip-australias-intent-130000148</guid>
<pubDate>Tue, 10 Feb 2026 13:00:00 GMT</pubDate>
<description>Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that IP Australia, the Australian government agency responsible for administering Australia's intellectual property rights system, has issued a Notice of Acceptance, on February 5, 2026, of the Genprex patent application claiming the use of Reqorsa® Gene Therapy in combination with PD-L1 antibodies fo</description>
</item>
<item>
<title>Genprex Provides Clinical Update on Diabetes Gene Therapy Program</title>
<link>https://6ix.com/company/genprex-inc/news/genprex-provides-clinical-diabetes-gene-120000971</link>
<guid isPermaLink="true">https://6ix.com/company/genprex-inc/news/genprex-provides-clinical-diabetes-gene-120000971</guid>
<pubDate>Wed, 07 Jan 2026 12:00:00 GMT</pubDate>
<description>Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced a clinical program update on its diabetes gene therapy program for GPX-002, the Company's diabetes gene therapy drug candidate, detailing recent achievements and future advancements. This update follows the recent announcement of positive preliminary preclinical data from studies of GPX-002 in both mo</description>
</item>
<item>
<title>Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies</title>
<link>https://6ix.com/company/genprex-inc/news/genprex-announces-positive-preliminary-preclinical-120000519</link>
<guid isPermaLink="true">https://6ix.com/company/genprex-inc/news/genprex-announces-positive-preliminary-preclinical-120000519</guid>
<pubDate>Tue, 06 Jan 2026 12:00:00 GMT</pubDate>
<description>Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients...</description>
</item>
<item>
<title>Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer</title>
<link>https://6ix.com/company/genprex-inc/news/data-genprexs-acclaim-1-phase-120000525</link>
<guid isPermaLink="true">https://6ix.com/company/genprex-inc/news/data-genprexs-acclaim-1-phase-120000525</guid>
<pubDate>Mon, 24 Nov 2025 12:00:00 GMT</pubDate>
<description>Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the publication of data from its Acclaim-1 Phase 1 clinical trial of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with Tagrisso® (osimertinib) in patients with advanced non-small cell lung cancer (NSCLC) in the peer-reviewed journal Clinical Lung Cancer.</description>
</item>
<item>
<title>Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials</title>
<link>https://6ix.com/company/genprex-inc/news/genprex-adds-clinical-trial-acclaim-120000419</link>
<guid isPermaLink="true">https://6ix.com/company/genprex-inc/news/genprex-adds-clinical-trial-acclaim-120000419</guid>
<pubDate>Wed, 19 Nov 2025 12:00:00 GMT</pubDate>
<description>Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company has added Gabrail Cancer Center in Canton, Ohio, as a new clinical trial site for the Acclaim-1 and Acclaim-3 clinical trials studying its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), in lung cancer. In addition, the Company expects to add and open additional clin</description>
</item>
<item>
<title>Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers</title>
<link>https://6ix.com/company/genprex-inc/news/genprex-announces-u-patent-reqorsa-120000899</link>
<guid isPermaLink="true">https://6ix.com/company/genprex-inc/news/genprex-announces-u-patent-reqorsa-120000899</guid>
<pubDate>Tue, 18 Nov 2025 12:00:00 GMT</pubDate>
<description>Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the United States Patent and Trademark Office (USPTO) has granted Genprex a patent that covers the use of the Company's lead drug candidate, Reqorsa® Gene Therapy, in combination with PD-L1 antibodies, such as Tecentriq®, through 2037.</description>
</item>
<item>
<title>Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer</title>
<link>https://6ix.com/company/genprex-inc/news/genprex-announces-european-patent-offices-120000693</link>
<guid isPermaLink="true">https://6ix.com/company/genprex-inc/news/genprex-announces-european-patent-offices-120000693</guid>
<pubDate>Tue, 04 Nov 2025 12:00:00 GMT</pubDate>
<description>Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the European Patent Office (EPO) has communicated its intent to grant Genprex a patent for the use of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with PD-1 antibodies for the treatment of cancer.</description>
</item>
<item>
<title>Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/genprex-inc/news/genprex-announces-registered-direct-offering-151900271</link>
<guid isPermaLink="true">https://6ix.com/company/genprex-inc/news/genprex-announces-registered-direct-offering-151900271</guid>
<pubDate>Tue, 28 Oct 2025 15:19:00 GMT</pubDate>
<description>Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into definitive agreements for the issuance and sale of 377,780 shares of common stock at a purchase price of $9.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered short-term w</description>
</item>
<item>
<title>Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics</title>
<link>https://6ix.com/company/genprex-inc/news/genprex-collaborators-report-positive-preclinical-110000453</link>
<guid isPermaLink="true">https://6ix.com/company/genprex-inc/news/genprex-collaborators-report-positive-preclinical-110000453</guid>
<pubDate>Tue, 28 Oct 2025 11:00:00 GMT</pubDate>
<description>Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for Reqorsa® Gene Therapy (quaratusugene ozeplasmid) for the treatment of ALK-EML4 positive (ALK+) non-small cell lung cancer (NSCLC).</description>
</item>
<item>
<title>Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/genprex-inc/news/genprex-announces-registered-direct-offering-121200691</link>
<guid isPermaLink="true">https://6ix.com/company/genprex-inc/news/genprex-announces-registered-direct-offering-121200691</guid>
<pubDate>Thu, 23 Oct 2025 12:12:00 GMT</pubDate>
<description>Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into definitive agreements for the issuance and sale of 243,622 shares of common stock at a purchase price of $11.21 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered short-term</description>
</item>
<item>
<title>Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics</title>
<link>https://6ix.com/company/genprex-inc/news/genprex-collaborators-present-positive-preclinical-110000686</link>
<guid isPermaLink="true">https://6ix.com/company/genprex-inc/news/genprex-collaborators-present-positive-preclinical-110000686</guid>
<pubDate>Thu, 23 Oct 2025 11:00:00 GMT</pubDate>
<description>Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present positive preclinical data at the upcoming 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 22-26, 2025 at the Hynes Convention Center in Boston. The collaborators will present positive preclinica</description>
</item>
<item>
<title>Genprex to Present and Participate at Upcoming September Investor and Industry Conferences</title>
<link>https://6ix.com/company/genprex-inc/news/genprex-present-participate-upcoming-september-123000147</link>
<guid isPermaLink="true">https://6ix.com/company/genprex-inc/news/genprex-present-participate-upcoming-september-123000147</guid>
<pubDate>Tue, 02 Sep 2025 12:30:00 GMT</pubDate>
<description>Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences being held in September 2025.</description>
</item>
<item>
<title>Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers</title>
<link>https://6ix.com/company/genprex-inc/news/genprex-receives-notice-allowance-multiple-132900658</link>
<guid isPermaLink="true">https://6ix.com/company/genprex-inc/news/genprex-receives-notice-allowance-multiple-132900658</guid>
<pubDate>Mon, 18 Aug 2025 13:29:00 GMT</pubDate>
<description>Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent to Genprex that covers the use of the Company's lead drug candidate, Reqorsa® Gene Therapy, in combination with PD-L1 antibodies, such as Tecentriq®. Similarly, the European Patent Office has issued a Notice of All</description>
</item>
</channel>
</rss>